Esophageal cancer
Conditions
Interventions
Experimental Group:Radiotherapy combined with S-1 and nimotuzumab
Sponsors
Zhejiang Cancer Hospital
Eligibility
Sex/Gender
All
Age
70 Years to No maximum
Inclusion criteria
Inclusion criteria: The primary tumor was pathologically confirmed to be esophageal squamous cell carcinoma. 2.Charlson=4 points 3.AJCC/UICC Esophageal Cancer Staging (6th Edition) Clinical stage IIA to IVA. 4. Patients who are not suitable for surgery or who are eligible for surgery but refuse it. 5. Age >=70 years old. 6. The ECOG physical condition score ranges from 0 to 1. 7. There was no esophageal perforation or active esophageal bleeding, and no invasion of the trachea or major blood vessels in the thoracic cavity. 8. No previous chest chemotherapy, radiotherapy, immunotherapy or biological therapy has been administered. Serum hemoglobin >=100g/L, platelet count >=10×10^9/L, absolute neutrophil count >=1.5×10^9/L 10. Serum creatinine =60 mL/ min. Serum bilirubin =0.8L. 13. Patients sign the formal informed consent form to indicate that they understand this study complies with the hospital's policy and ethical requirements.
Exclusion criteria
Exclusion criteria: 1. Before the start of treatment in this trial, the patient had received chest radiotherapy, chemotherapy or surgical resection of esophageal cancer 2. Patients with esophageal cancer whose primary lesion is multifocal 3. The lower boundary of the primary esophageal lesion is less than 3cm away from the esophagogastric junction 4. Patients with severe cardiovascular or lung diseases. 5. Patients who cannot understand the trial requirements or may not comply with them 6. Abdominal lymph node metastasis 7. Those who have lost more than 10-15% of their weight 8. People with long-term poor blood sugar control due to diabetes 10. It is known that there is an allergic reaction of grade 3 to 4 to any treatment stage 11. Participated in other clinical trials within the past 30 days 12. Patients aged 80 or above with a score of 5 in the NRS2002 nutritional risk screening 13. Patients aged 80 or above, accompanied by diabetes, or chronic lung disease (such as chronic bronchopneumonia), or a history of myocardial infarction/congestive heart failure, or cerebrovascular disease 14. Some obvious diseases that the researchers believe should be excluded from this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression Free Survival;Short-term effect;Quality of life;Failure mode;Toxicities; | — |
Countries
China
Contacts
Public ContactQiu Guoqin
Zhejiang Cancer Hospital
Outcome results
None listed